Volume 15 (2017): Issue 8 (Aug 2017)

in Journal of the National Comprehensive Cancer Network
Online ISSN:
1540-1413
Print ISSN:
1540-1405
Cover Journal of the National Comprehensive Cancer Network
NCCN News
Pages: xxvii–xxix
Oncology Research Program
Pages: xxxv–xxxvi
When It's Really Good, We Know It!
By: Margaret Tempero
Pages: 973
To the Editor: How Do We Solve This Confusion?
Pages: 975–976
Targeted MAPK Pathway Inhibitors in Patients With Disseminated Pilocytic Astrocytomas
By: Anastasia Drobysheva, Laura J. Klesse, Daniel C. Bowers, Veena Rajaram, Dinesh Rakheja, Charles F. Timmons, Jason Wang, Korgun Koral, Lynn Gargan, Erica Ramos, and Jason Y. Park
Pages: 978–982
Neoadjuvant Treatment With Trastuzumab and FOLFOX Induces a Complete Pathologic Response in a Metastatic ERBB2 (HER2)-Amplified Duodenal Cancer
By: Ahmad Hamad, Aatur D. Singhi, Nathan Bahary, Kevin McGrath, Rula Amarin, Herbert J. Zeh, and Amer H. Zureikat
Pages: 983–988
NCCN Guidelines Insights: Palliative Care, Version 2.2017
By: Maria Dans, Thomas Smith, Anthony Back, Justin N. Baker, Jessica R. Bauman, Anna C. Beck, Susan Block, Toby Campbell, Amy A. Case, Shalini Dalal, Howard Edwards, Thomas R. Fitch, Jennifer Kapo, Jean S. Kutner, Elizabeth Kvale, Charles Miller, Sumathi Misra, William Mitchell, Diane G. Portman, David Spiegel, Linda Sutton, Eytan Szmuilowicz, Jennifer Temel, Roma Tickoo, Susan G. Urba, Elizabeth Weinstein, Finly Zachariah, Mary Anne Bergman, and Jillian L. Scavone
Pages: 989–997
Race- and Sex-Based Disparities in the Therapy and Outcomes of Squamous Cell Carcinoma of the Anus
By: Nivedita Arora, Arjun Gupta, Hong Zhu, Alana Christie, Jeffrey J. Meyer, Saad A. Khan, and Muhammad S. Beg
Pages: 998–1004
The Evolution of Metastatic Colorectal Cancer Clinical Trials: Application of the ASCO Framework for Assessing Value
By: Doreen A. Ezeife, Sunil Parimi, Ellen R. Cusano, Matthew K. Smith, Tony H. Truong, Soundouss Raissouni, Yongtao Lin, Jose G. Monzon, Haocheng Li, Vincent C. Tam, and Patricia A. Tang
Pages: 1005–1013
Costs and Benefits of Extended Endocrine Strategies for Premenopausal Breast Cancer
By: Janice S. Kwon, Gary Pansegrau, Melica Nourmoussavi, Geoffrey L. Hammond, and Mark S. Carey
Pages: 1015–1021
Short- and Long-Term Survival in Metastatic Pancreatic Adenocarcinoma, 1993–2013
By: Talia Golan, Tal Sella, Ofer Margalit, Uri Amit, Naama Halpern, Dan Aderka, Einat Shacham-Shmueli, Damien Urban, and Yaacov Richard Lawrence
Pages: 1022–1027
Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology
By: Margaret A. Tempero, Mokenge P. Malafa, Mahmoud Al-Hawary, Horacio Asbun, Andrew Bain, Stephen W. Behrman, Al B. Benson III, Ellen Binder, Dana B. Cardin, Charles Cha, E. Gabriela Chiorean, Vincent Chung, Brian Czito, Mary Dillhoff, Efrat Dotan, Cristina R. Ferrone, Jeffrey Hardacre, William G. Hawkins, Joseph Herman, Andrew H. Ko, Srinadh Komanduri, Albert Koong, Noelle LoConte, Andrew M. Lowy, Cassadie Moravek, Eric K. Nakakura, Eileen M. O'Reilly, Jorge Obando, Sushanth Reddy, Courtney Scaife, Sarah Thayer, Colin D. Weekes, Robert A. Wolff, Brian M. Wolpin, Jennifer Burns, and Susan Darlow
Pages: 1028–1061
DNA Repair Dysfunction in Pancreatic Cancer: A Clinically Relevant Subtype for Drug Development
By: Talia Golan and Milind Javle
Pages: 1063–1069
Trends in Neoadjuvant Approaches in Pancreatic Cancer
By: Lingling Du and Andrea Wang-Gillam
Pages: 1070–1077
Acting on Rare Driver Alterations: Is Getting a Meaningful Response a Game of Chance or Scientific Rigor?
By: David R. Braxton
Pages: 1078–1080
  • Collapse
  • Expand